News

Gilead to acquire Nimbus Apollo

BY David Salazar
FOSTER CITY, Calif. — Gilead Sciences announced Monday that it would be acquiring Nimbus Apollo, a subsidiary of Nimbus Therapeutics, and its program working on developing an Acetyl-CoA Carboxylase (ACC) inhibitor. 
 
The program includes a lead candidate for an ACC inhibitor to treat the liver disease non-alcoholic steatohepatitis (NASH), which affects up to 15 million people in the U.S., and as a potential treatment for hepatocellular carcinoma. The Food and Drug Administration has given the candidate Fast Track designation and Phase 1 data is set to be presented in May at the International Liver Congress 2016. 
 
“The acquisition of Nimbus’ ACC-inhibitor program represents a timely and important opportunity to accelerate Gilead’s ongoing efforts to address unmet needs in NASH,” Gilead EVP research and development and chief scientific officer Norbert Bischofberger said. “These molecules will complement and further strengthen Gilead’s pipeline and capabilities to advance a broad clinical program in NASH that includes compounds targeting multiple key pathways involved in the pathogenesis of the disease.”
 
When the acquisition is complete, Nimbus Apollo will be owned by Gilead and Nimbus Therapeutics will retain ownership of its other research and development subsidiaries. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

New Honey Maid campaign underscores acceptance

BY Gina Acosta

EAST HANOVER, N.J. — Honey Maid is embarking on the third year of its "This Is Wholesome" campaign, appealing to consumers with stories of families who have been brought closer together through one thing: acceptance.

"Our new campaign creative taps into a cultural insight that is rooted in the change of the American family dynamic," said Katrina Plummer, equity brand manager, Honey Maid, Mondelez International. "In 2016, we're encouraging Americans to view the world through the eyes of acceptance – and remember that no matter how families might change, just like our products, what makes them wholesome remains the same."

The omnichannel campaign features five real American families (one of which is pictured above) – including those that spotlight an adopted son, a disabled veteran, a Hispanic gay couple and neighbors of different cultures – each sharing their story of acceptance with the intent of inviting viewers to think about acceptance in their own lives.

Honey Maid is also introducing the Wholesome Button: a browser app that allows users to experience the Internet through the lens of acceptance and positivity. Once added, users simply click the "Wholesomize It" bookmark in their bookmarks bar anytime they desire to replace images and headlines on their screen with content celebrating love, family connections and acceptance.

"This tool truly allows users to view the Internet through the lens of acceptance and positivity, something that is part of our brand DNA," said Plummer. "By giving people the opportunity to connect with our campaign and share a reimagined world, we hope to bring wholesome families closer together, invite people to think about acceptance in their own lives and even start a dialogue with someone within their own family or community that they have struggled to accept."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

McKesson completes Vantage Oncology, Biologics acquisitions

BY David Salazar
SAN FRANCISCO — McKesson announced Monday that it had completed its acquisitions of both Biologics and Vantage Oncology for $1.2 billion. 
 
McKesson, when announcing the acquisitions in February, noted that they would increase the scale of its specialty pharmaceutical distribution, its oncology-focused pharmacy offerings, manufacturer and payer solutions and the scope of community-based oncology and practice management services for providers and patients. 
 
“McKesson is committed to the success of our community oncology partners and customers and we believe the acquisitions of Vantage and Biologics complement our holistic approach to providing best–in-class care for oncology patients,” McKesson chairman and CEO John Hammergren said when the deal was announced. 
 
Vantage Oncology adds more than 50 cancer centers to McKesson, as well as its comprehensive oncology management service model and a practice management model that it operates through joint ventures, sharing profits with partner physicians and hospitals. Biologics adds to the company its high-touch specialty pharmacy model, which provides controlled dispensing channels, including rapid and traceable pharmaceutical delivery solutions, increased analytics, and services for oncology patients, providing seamless care management.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?